Abstract
Some new 4β-N-heteroaryl analogues of podophyllotoxin have been prepared by employing Red Phosphorous/I2 reagent system. These 4β-N-heteroaryl analogues have been evaluated for their cytotoxicity against six human cancer cell lines and some representative ones have shown promising anticancer activity.
Keywords: Epipodophyllotoxin, benzothiazoles, pyrimidines, anticancer activity
Letters in Drug Design & Discovery
Title: Synthesis and Biological Activity of New 4β-N-Heteroaryl Analogues of Podophyllotoxin
Volume: 3 Issue: 3
Author(s): Ahmed Kamal, B. A. Kumar, M. Arifuddin and Sunanda G. Dastidar
Affiliation:
Keywords: Epipodophyllotoxin, benzothiazoles, pyrimidines, anticancer activity
Abstract: Some new 4β-N-heteroaryl analogues of podophyllotoxin have been prepared by employing Red Phosphorous/I2 reagent system. These 4β-N-heteroaryl analogues have been evaluated for their cytotoxicity against six human cancer cell lines and some representative ones have shown promising anticancer activity.
Export Options
About this article
Cite this article as:
Kamal Ahmed, Kumar A. B., Arifuddin M. and Dastidar G. Sunanda, Synthesis and Biological Activity of New 4β-N-Heteroaryl Analogues of Podophyllotoxin, Letters in Drug Design & Discovery 2006; 3 (3) . https://dx.doi.org/10.2174/157018006776286907
DOI https://dx.doi.org/10.2174/157018006776286907 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Advancements in Adjuvanticity of Bioactive Inorganic and Organic Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Angiogenesis and Metastasis Inhibitors for the Treatment of Malignant Melanoma
Mini-Reviews in Medicinal Chemistry Dynamical Behaviors of the Transcriptional Network Including REST and miR-21 in Embryonic Stem Cells
Current Bioinformatics Crystal Structures and Cytotoxicity of Ortho-Xylene Linked Bis-benzimidazolium Salts
Medicinal Chemistry Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Human Arylamine N-Acetyltransferase 1: A Drug-Metabolizing Enzyme and a Drug Target?
Current Drug Targets Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Synthesis and Evaluation of Novel Erucin Analogues as Potential Antitumor Compounds
Letters in Organic Chemistry Editorial: Metal ions in cause, progression, treatment and diagnosis of genetic disorders, metabolic diseases and cancer
Current Drug Metabolism Targeting βIII-Tubulin in Glioblastoma Multiforme: From Cell Biology and Histopathology to Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Copanlisib: Novel PI3K Inhibitor for the Treatment of Lymphoma
Anti-Cancer Agents in Medicinal Chemistry Pixuvri<sup>®</sup> (Pixantrone Dimaleate, BBR 2778): From Lab to Market
Current Organic Chemistry Gestational Programming of Offspring Obesity: A Potential Contributor to Alzheimers Disease
Current Alzheimer Research Malignant Mesothelioma: Biology, Diagnosis and Therapeutic Approaches
Current Molecular Pharmacology DNA Repair in Normal and Cancer Stem Cells, with Special Reference to the Central Nervous System
Current Medicinal Chemistry PRL-3, An Emerging Marker of Carcinogenesis, Is Strongly Associated with Poor Prognosis
Anti-Cancer Agents in Medicinal Chemistry Calcium Channels and Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews